31.67 USD
▲+0.70+7.14%
盘后 28.71 -2.88%
2026-08-03
市值
$2.04B
市盈率
—
EPS
-3.33
股息率
—
52 周区间
12.71 – 40.22
成交量
1.32M
Beta
1.23
目标价
45.82
52W 低 12.7152W 高 40.22
价格走势
公司简介
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i...